[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610821":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":42,"collaborators":19,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":19,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":19,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":67,"whyStopped":19,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Zhujiang Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Intranasal Administration of hUC-MSC-sEV-001 Therapy","EXPERIMENTAL","Intranasal Administration of Human Umbilical Cord Mesenchymal Stem Cell-Derived Small Extracellular Vesicles (hUC-MSC-sEV-001) Therapy",[13],"Biological: Intranasal Administration of Human Umbilical Cord Mesenchymal Stem Cell-Derived Small Extracellular Vesicles (hUC-MSC-sEV-001) Therapy",[15],{"type":16,"name":11,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","Experimental drug: hUC-MSC-SEV-001 nasal drops derived from small extracellular vesicles of human umbilical cord mesenchymal stem cells Treatment plan: On the basis of conventional treatment, hUC-MSC-SEV-001 nasal drops will be administered: hUC-MSC-SEV-001 will be administered via nasal drip for a total of 4 times, with a dosage of 1 × 10 \\* 11articles per dose. The patient will receive one dose on the day of enrollment, and another dose of hUC-MSC-SEV-001 will be administered on the 2nd, 3rd, and 4th days after enrollment.",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Run Zhang, Philosophy Doctor","CONTACT","+86 15820205853","Zrah@163.com",[27],{"facility":28,"status":19,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"253 Gongye Blvd Middle, Guangzhou, Guangdong, China 510280","Guangzhou","Guangdong","510000","China","CN",{"type":35,"coordinates":36},"Point",[37,38],113.25,23.11667,{"lat":38,"lon":37},[41],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},{"type":43,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100610821","phase-1-exploratory-study-of-intranasal-administration-of-human-umbilical-cord-mesenchymal-stem-cell-derived-extracellular-vesicles-for-the-treatment-of-ischemic-stroke-100610821",false,"NCT07232563","Exploratory Study of Intranasal Administration of Human Umbilical Cord Mesenchymal Stem Cell-Derived Extracellular Vesicles for the Treatment of Ischemic Stroke","Exploratory Study of Intranasal Administration of Small Extracellular Vesicles Derived From Human Umbilical Cord Mesenchymal Stem Cells hUC-MSC-sEV-001 in the Treatment of Ischemic Stroke Patients","Inclusion criteria:\n\n* Ischemic Stroke\n* Age 18-70 years, no gender restriction\n* Confirmed anterior circulation occlusion by CTA or MR angiography (MRA)\n* Pre-stroke mRS score of 0-1\n* Post-stroke ASPECTS score \\>= 6\n* Pre-enrollment NIHSS score\\>= 6\n* Within 24 hours to 14 days of stroke onset\n* Patients who have not received thrombolysis or endovascular treatment\n* No significant liver or kidney dysfunction: ALT and AST\\\u003C= 2.5 times the upper limit of normal, serum creatinine and blood urea nitrogen \\\u003C= 1.25 times the upper limit of normal\n* No significant cardiac dysfunction\n* The subject or legal representative can sign the informed consent form and comply with the requirements of the study for administration and follow-up.\n\nExclusion criteria:\n\n* Intracranial hemorrhagic conditions observed on cranial CT: hemorrhagic stroke, epidural hematoma, subdural hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, or hemorrhagic transformation, etc.\n* Known severe allergy to contrast agents (excluding mild rash-type allergies)\n* Known bleeding tendencies (including but not limited to): platelet count \\\u003C 100×10\\^9\u002FL; received heparin treatment within 48 hours with aPTT \\>= 35s; currently taking warfarin with INR \\> 1.7\n* Patients with brain tumors, or a history of epilepsy and severe head trauma\n* Patients with other systemic malignancies\n* Patients with other serious systemic diseases such as immunodeficiency, coagulation disorders, etc.\n* Patients with Alzheimer's disease, Parkinson's disease, or other neurodegenerative diseases that prevent them from completing follow-up\n* Patients with severe local infection, systemic infection, immunodeficiency, or those currently taking immunosuppressants\n* Patients who are positive for hepatitis B surface antigen or currently suffering from other infectious diseases\n* Patients who have allergic reactions to the drug used in this study or similar drugs\n* Patients with known allergic constitution\n* Patients with nasal structural abnormalities or lesions\n* Patients with cerebrospinal fluid rhinorrhea\n* Patients who have participated in other clinical trials within the past 3 months\n* Unwilling or unable to comply with the procedures specified in the protocol\n* Pregnant or breastfeeding women, or women of childbearing potential who are unwilling or unable to use appropriate contraceptive measures\n* Patients clearly lacking the compliance to complete the clinical trial, such as those suffering from uncontrolled mental illness\n* Other situations deemed unsuitable for enrollment by the researchers","ALL","18 Years","70 Years",{"count":55,"type":56},9,"ESTIMATED","INTERVENTIONAL",[59],"PHASE1","Evaluation of the Safety and Preliminary Efficacy of Intranasal Administration of Human Umbilical Cord Mesenchymal Stem Cell-Derived Small Extracellular Vesicles (hUC-MSC-sEV-001) in Patients for Ischemic Stroke",[62],"Ischemic Stroke",[64,65,66],"ischemic stroke","stem cell","Extracellular Vesicles","NOT_YET_RECRUITING","2025-11-14",{"date":70,"type":71},"2025-11-18","ACTUAL",{"date":73,"type":56},"2025-12-01",{"date":75,"type":56},"2027-11-07",{"name":5,"class":6},1]